Blog

  • Fence and Deck Depot Unveils Mold-Resistant Option for Unmatched Durability in St. Charles, MO

    Fence and Deck Depot Unveils Mold-Resistant Option for Unmatched Durability in St. Charles, MO

    Fence and Deck Depot, located in St. Charles, Missouri, is rolling out a new line of mold-resistant decking this fall. This addition responds to the increasing humidity that often creates challenges for homeowners. Their goal is to offer durable and practical products for outdoor living spaces.

    As the weather shifts and humidity rises, mold tends to become a common issue for deck owners. Fence and Deck Depot is addressing this problem by offering mold-resistant decking materials. These materials are crafted to endure the tough conditions typical of the fall season. Homeowners in St. Charles and nearby areas can look forward to an easier maintenance routine and less worry.

    The mold-resistant decking brings a lot to the table. By keeping mold at bay, it holds onto its look and lasts longer than traditional materials. This means fewer cleaning tasks and maintenance jobs. This new option shows the company’s commitment to meeting the changing needs of their customers.

    “We’re excited to bring mold-resistant decking to our clients,” a representative from Fence and Deck Depot said. “We want to help people make the most of their outdoor areas without worrying about upkeep during the change of seasons. This material not only boosts a home’s look but also provides sturdy, long-term protection.”

    This launch fits into Fence and Deck Depot’s larger plan to broaden their deck offerings. They also have a variety of deck styles and materials, such as composite, vinyl, and wood. By adding this mold-resistant technology, they show their commitment to top-notch service and customer satisfaction.

    Fence and Deck Depot doesn’t just stop at decks. They’re a leading name among St. Charles, MO Deck Builders and also provide all kinds of fencing solutions. They install everything from privacy and pool fences to garden fences using wood, aluminum, and vinyl. Each product is made with an eye for detail, making sure they look good and serve their purpose well.

    “Our team is dedicated to offering outdoor solutions that are both beautiful and dependable,” the media relations representative added. “Adding mold-resistant decking fits right in with this promise. We believe it will greatly improve our customers’ outdoor experiences.”

    This new mold-resistant decking highlights Fence and Deck Depot’s status as a trusted name in outdoor home improvements. They stick to their mission of delivering top-notch service and products to clients in both Missouri and Illinois.

    For anyone interested in upgrading to mold-resistant decking, more details are available on their website. The site offers full information about their services and the materials they offer for decks and fences. They also encourage potential clients to reach out for a consultation to discuss individual needs and explore suitable materials.

    With over 20 years of experience, Fence and Deck Depot has made a name for itself in the world of outdoor home improvements. They keep finding ways to innovate and adapt to what homeowners need. This new addition to their products works as a strong defense against the weather, enhancing how enjoyable outdoor spaces can be. Customers in the area are welcome to see this advancement and the peace of mind it offers. Visit their website for more information about their services and to schedule a consultation.

    Revent News: Fence and Deck Depot’s Essential Guide: How to Fix Backyard Safety Hazards and Make Them Safe for The Family

    The post Fence and Deck Depot Unveils Mold-Resistant Option for Unmatched Durability in St. Charles, MO appeared first on Local News Hub.

  • Commonwealth M&A Welcomes Industry Veteran Joe DiGiacomo As Senior Advisor & Managing Director

    Commonwealth M&A Welcomes Industry Veteran Joe DiGiacomo As Senior Advisor & Managing Director

    The new relationship brings extensive experience to elevate client offerings and support future growth

    PHILADELPHIA, PA / ACCESS Newswire / August 19, 2025 / Commonwealth M&A, LLC, a premier full-service Merger & Acquisition advisory firm providing transactional and valuation services to small and medium sized businesses, today announced that Joe DiGiacomo has joined the team as a Senior Advisor and Managing Director. DiGiacomo will play a key role in company operations managing specific transactions, and will also offer counsel on other transactions, utilizing his 40+ years of experience to ensure deals close smoothly, companies get the valuation they deserve, and sellers are optimized to secure the best transition for their business.

    A seasoned professional who is well-established in the lower middle market, DiGiacomo has a diverse background in investment banking, business valuation, accounting, and mergers and acquisitions. Most recently as the Founder and President of D5 Capital Advisors, a boutique lower middle market M&A advisory firm headquartered in the Lehigh Valley, as well as previous positions as the President and CFO of a $135 million multimodal transportation and logistics business, and Partner of a regional CPA firm.

    “Our goals for Commonwealth M&A have been big from the start and bringing Joe on our team is going to supercharge our capabilities,” said Rick Calabrese, co-founder of Commonwealth M&A. “Having previously worked with Joe in my capacity as a transactional attorney, I know first hand the wealth of knowledge and experience he brings to the table. We are excited to add his expertise to our team to continue to bring our clients exceptional results, which is always our top priority.”

    “When I was considering combining my practice with another firm, I knew I wanted to join a team that was talented and motivated. I had worked with Rick in the past and when I found out he had started his own firm, I immediately wanted to learn more. I met with him and Joe [Bergin] and the pieces just fell into place, their mindset and business approach is exactly what I was looking for,” commented Joe DiGiacomo. “This team knows what they’re doing and I really think that their energy and technical experience paired with my background is going to be a dynamic offering. I’m very excited about this new chapter and know there’s an extremely bright future ahead for Commonwealth M&A.”

    In the last calendar year alone, Commonwealth M&A has closed more than $50M in transaction value for clients. Founders Rick Calabrese and Joe Bergin both offer unique expertise, Calabrese as a transactional attorney and CPA, and Bergin with a decade of corporate M&A experience at Johnson & Johnson. The team believes they can leverage DiGiacomo’s broad expertise to help lower middle market businesses find a deal that fits all of their needs.

    About Commonwealth M&A, LLC
    Commonwealth M&A, LLC is a full-service Merger & Acquisition advisory firm providing transactional and valuation services to small and medium-sized businesses. Commonwealth M&A offers a differentiated approach derived from the team’s diverse set of experiences. Our mission is to deliver personalized, high-quality service that exceeds expectations. Visit us at https://commonwealthmna.com/

    Media Contact
    Martina Corona
    Martina@notablypr.com

    SOURCE: Commonwealth M&A

    View the original press release on ACCESS Newswire

    The post Commonwealth M&A Welcomes Industry Veteran Joe DiGiacomo As Senior Advisor & Managing Director appeared first on Local News Hub.

  • Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)

    Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)

    As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating MVID patient by up to 27%; abstract describing results accepted for presentation at upcoming North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) 2025 Annual Meeting in Chicago

    SAN FRANCISCO, CA / ACCESS Newswire / August 19, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that it plans to meet with the U.S. Food and Drug Administration (FDA) to discuss the company’s ongoing clinical development program for crofelemerfor the treatment of microvillus inclusion disease (MVID), an ultrarare pediatric disorder. Members of Napo’s Scientific Advisory Board will join Napo and Jaguar representatives at the meeting.

    “We’re very pleased that Napo has been granted a meeting with the FDA to discuss Napo’s development plans for crofelemer for MVID – a devastating pediatric disease characterized by severe malabsorption that requires life-sustaining parenteral support to meet the nutritional, fluid and electrolyte requirements of the child, and for which there no approved drug treatments,” said Pravin Chaturvedi, PhD, Napo’s and Jaguar’s Chief Scientific Officer and Chair of the Scientific Advisory Board. “A core Napo goal for this meeting is to obtain input from the FDA on the clinical program and potential expedited regulatory pathways for this rare orphan indication.”

    As announced, and as presented April 26, 2025 at the Annual ELITE PED-GI Congress, the initial proof-of-concept results of the ongoing investigator-initiated trial (IIT) of a novel crofelemer powder formulation for oral solution in Abu Dhabi in the United Arab Emirates show that crofelemer reduced the required total parenteral nutrition (TPN) and supplementary intravenous fluids in the first participating MVID patient by up to 27%. An abstract describing the initial results of this trial has been accepted for presentation at the upcoming North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting taking place November 5-8, 2025 in Chicago.

    Jaguar, through Napo, is supporting the independent proof-of-concept IIT in pediatric intestinal failure (IF) patients at Sheikh Khalifa Medical City in Abu Dhabi, and is conducting the placebo-controlled Phase 2 study of crofelemer in pediatric MVID patients with IF at sites in the U.S., European Union, and Middle East/North Africa regions under appropriate regulatory approvals in each of these geographies.

    “Given the ultrarare nature of MVID, and the groundbreaking initial proof-of-concept results from the IIT in Abu Dhabi, even a small number of MVID patients showing benefit with crofelemer may allow Napo to explore pathways for expedited regulatory approval,” said Lisa Conte, Jaguar’s Founder and CEO.

    Based on the initial findings from the IIT in Abu Dhabi, crofelemer’s paradigm-shifting mechanism of action has the potential to provide a novel therapeutic option to reduce parenteral support and associated complications in MVID patients.

    About the Jaguar Health Family of Companies

    Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including MVID and short bowel syndrome.

    For more information about:

    Jaguar Health, visit https://jaguar.health

    Napo Pharmaceuticals, visit www.napopharma.com

    Napo Therapeutics, visit napotherapeutics.com

    Forward-Looking Statements

    Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that Napo personnel will meet with the FDA to discuss Napo’s development plans for crofelemer for MVID, statements regarding Jaguar’s expectation that an abstract describing the results of the investigator-initiated trial in Abu Dhabi will be presented at NASPGHAN 2025, Jaguar’s expectation that even a small number of MVID patients showing benefit with crofelemer may allow Napo to explore pathways for expedited regulatory approval, and Jaguar’s expectation that crofelemer’s paradigm-shifting mechanism of action has the potential to provide a novel therapeutic option to reduce parenteral support and associated complications in MVID patients. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

    Contact:

    hello@jaguar.health
    Jaguar-JAGX

    SOURCE: Jaguar Health, Inc.

    View the original press release on ACCESS Newswire

    The post Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID) appeared first on Local News Hub.

  • MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage

    MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage

    Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025

    MIAMI, FL / ACCESS Newswire / August 19, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced the successful completion of the Single Ascending Dose (SAD) portion of its ongoing Phase 1 clinical trial evaluating oral Ketamir-2. The study, conducted at the Hadassah Clinical Research Center in Israel under the direction of Principal Investigator Prof. Yoseph Caraco, demonstrated a favorable safety and tolerability profile, with no severe or clinically significant adverse effects observed to date.

    “Completion of the SAD portion with a favorable safety and tolerability profile is an important milestone in the clinical development of Ketamir-2,” said Prof. Yoseph Caraco, Principal Investigator of the Phase 1 study. “Importantly, no severe or clinically significant adverse effects have been observed to date, which supports continued progression into the Multiple Ascending Dose stage of the trial.”

    Phase 1 Study Overview

    The study- “A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Centre Study of Single and Repeated Dosing of Ascending Doses, to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral Ketamir-2 in Healthy Adult Subjects“-is designed to establish the safety, tolerability, and pharmacokinetics of Ketamir-2 in healthy adult volunteers.

    • Design: Single-center, randomized, double-blind, placebo-controlled SAD/MAD with sentinel dosing and Safety Steering Committee (SSC) reviews between cohorts.

    • SAD completed: Four cohorts (single doses 50 mg to 600 mg); 32 participants treated (male and female).

    • Safety monitoring: Extensive central nervous system (CNS) safety assessments were performed using well-validated clinical research tools:

      • Columbia-Suicide Severity Rating Scale (C-SSRS) – screens for suicidal ideation or behavior, supporting early detection of potential mood or psychiatric changes.

      • Bowdle Visual Analogue Scale (VAS) – measures possible psychedelic or dissociative effects sometimes seen with ketamine and related compounds.

      • Ketamine Side Effect Tool (KSET) – tracks a broad range of known ketamine-related side effects over time, including sensory, cognitive, and mood changes.
        These tools provided multiple, complementary layers of safety evaluation to help detect even subtle CNS effects throughout the trial.

    • Status: To date, no severe or clinically significant adverse effects have been observed at any dose level in the SAD portion of the study.

    While the study remains ongoing and blinded, it is worth noting that, across the pharmaceutical industry as a whole, approximately one-third of investigational drugs fail during Phase 1 due to safety concerns (Tufts Center for the Study of Drug Development). These interim observations provide encouraging context as MIRA advances Ketamir-2 through the next stage of clinical evaluation, consistent with the Company’s mission to prioritize safety in every step of development.

    The Company is advancing to the Multiple Ascending Dose (MAD) portion, which will evaluate three cohorts receiving daily oral doses of 150 mg, 300 mg, or 600 mg for five consecutive days in up to 24 participants.

    “The emerging human safety profile complements the preclinical data we’ve generated, which show Ketamir-2’s superior efficacy in multiple neuropathic pain models without triggering the hallmark CNS side effects of ketamine,” said Dr. Itzchak Angel, Chief Scientific Advisor of MIRA. “This combination of efficacy, safety, and oral delivery positions Ketamir-2 as a promising next-generation treatment for neuropathic pain and potentially other CNS disorders.“

    Strategic & Commercial Potential

    Ketamir-2 is a proprietary, orally bioavailable new molecular entity that selectively targets the NMDA receptor (PCP site) with low affinity and shows no significant off-target activity across a broad receptor panel. Preclinical studies have demonstrated superior performance versus ketamine, pregabalin, or gabapentin (depending on comparator and model) in gold-standard neuropathic pain models-without the dissociative effects associated with ketamine.

    Neuropathic pain affects an estimated 36-51 million people in North America and represents a multi-billion-dollar market today, with long-term growth driven by diabetes prevalence, cancer survivorship, and aging-related nerve damage. MIRA intends to submit a Phase 2a clinical protocol in neuropathic pain by year-end 2025 and continue evaluating potential applications in depression, anxiety, PTSD, and localized pain, subject to ongoing results and regulatory feedback.

    “We are pleased to see our Phase 1 program progress as planned,” said Erez Aminov, CEO of MIRA. “Advancing into the MAD stage is an important operational step as we continue to build a rigorous safety and PK foundation for Ketamir-2 and work to deliver a differentiated, non-opioid option for patients with neuropathic pain.“

    About MIRA Pharmaceuticals, Inc.

    MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company’s pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline.

    For more information, please visit www.mirapharmaceuticals.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release and the statements of MIRA’s management related thereto contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA’s control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA’s potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA’s programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at www.sec.gov and on MIRA’s website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

    Contact:
    Helga Moya
    info@mirapharma.com
    (786) 432-9792

    SOURCE: MIRA Pharmaceuticals

    View the original press release on ACCESS Newswire

    The post MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage appeared first on Local News Hub.

  • Sunseeker Launches Robotic Mowers on Lowe’s Online Platform

    Sunseeker Launches Robotic Mowers on Lowe’s Online Platform

    CHARLOTTE, NC / ACCESS Newswire / August 19, 2025 / Most Sunseeker Tech products, including the X7 Series of state-of-the-art robotic mowers, can now be purchased online as a part of the new partnership between Sunseeker Tech and Lowe’s. This partnership marks a significant step in expanding Sunseeker’s reach to more homeowners in the United States. It offers innovative solutions with its advanced lawn care machines.

    “At Sunseeker, robotic lawn care is the norm, not the exception. The collaboration with Lowe’s will enable us to target more homeowners than ever before, giving them the ease, accuracy, and sustainability,” said the CEO.

    Putting Smart Lawn Care in More Lawns

    With the collaboration between Lowe’s and Sunseeker, the company would turn a new leaf in its quest to popularize robotic mowing as an option among housekeepers. Lowe’s is the most recognized online shopping platform in home improvement in America.

    It offers the best medium to reach the tech-savvy segment of consumers eager to find sustainable and efficient form of maintaining their property. This will allow customers in Charlotte and beyond to buy robotic mowers. This ensure professional-quality results with minimum human interaction.

    Features of Sunseeker X7 Series

    Among the product line, X7 Series is a fully autonomous robot lawn mower designed to provide unique lawn care experience, with highly advanced AI technology, RTK (Real-Time Kinematic) navigation and high-grade engineering.

    It is unique due to the following features:

    • Adaptive AI Mowing Patterns: The mower learns and can adapt to growth of the grass, weather and obstacles providing smooth and consistent cutting

    • RTK-level Accuracy: Operates at sub-centimeter campus-wide accuracy without the use of perimeter wires. It can reduce cost on an installation and enhance dependability

    • Smart Collision Sensing: Automatically senses pets, children, and garden decor and goes around them unhindered

    • All-Weather Performance: The construction is designed to work in any kind of weather with rain sensors and IPX durability rating

    The electric, less noisy motor of the X7 does not only limit environmental interference but also promotes silent work. It is a vehicle-friendly in the neighborhoods. With a companion mobile app, homeowners can view, schedule, and control their mower remotely from anyplace, welcoming it to their smart home system.

    High-End, Low Pressure

    The mission of Sunseeker is not just a grass cutting machine but about giving back time to people. The CEO said that the target was to assist homeowners in reclaiming their weekends. You will never have to worry about your lawn with Sunseeker. You can rest in knowing that you have one less thing to worry about because your lawn is well taken care of.

    Whether on tightly trimmed urban gardens or expansive suburban gardens, the X7 is able to adjust to all set-ups. It can move over hills, rugged land, and different types of grasses easily. That is why it is good both in residential areas, Charlotte neighborhood, and golf resort spaces.

    Making Lawn Care Futuristic

    Robotic mowing has a positive impact on the world. Not only does it make life easier, but also helps create a healthier planet. When homeowners upgrade their gas mowers to battery-operated ones such as the X7, they reduce noise pollution caused by emissions.

    Its smart scheduling of the mower also ensures that whether it cuts the lawn more often or less, it is healthy without any extra energy. This increased enthusiasm among consumers on eco-friendly technology that can sustain the lifestyle without sacrificing performance.

    More Smarter Lawn Care

    Sunseeker expects to be an entirely incorporated player in the smart home ecosystem. The company’s vision is that its mowers will interact with other smart devices and adapt intelligently to the shifts in the environment. It is also to present hyper-personalized mowing formats to the yard. As the company continues to innovate, it will continue to add more products to its line. It seeks to address the requirements of all kinds of homeowners, whether of a small city plot or large estate.

    Availability

    TheLowe’s online store now offers the Sunseeker robotic mowers, such as the X7 Series which is the more advanced version of their product line. Customers will have access to product specifications, models to compare, and convenience of shipping and customer services offered by Lowe’s.

    To know more about the products of Sunseeker, you can visit the site www.sunseekertech.com Follow the brand on social media to get acquainted with the latest news, user experience, and views:

    About Sunseeker Robotic Technology

    Sunseeker Robotic Technology will ensure it is a pioneer in smart yard technology recreating the outdoor living experience with the ideal totality of current robotics, AI navigation engineering, and green engineering. Its premium X7 Series robotic mower is the benchmark of accuracy, adaptability, and convenience in a robot mower. This makes it more versatile to the homeowner that cares about performance and sustainability.

    Coupled with the drive to undeniably innovate and make its customers happy, Sunseeker is constantly exploring ways to automate exterior maintenance. So, people spend less time maintaining their lawns and more time enjoying them.

    Media Details:
    Website URL: sunseekertech.com
    Company Name: Sunseeker North America
    Email address: marketing.global@sunseekertech.com
    Address: 4330 Matthews Indian Trail Rd STE A
    Indian Trail, NC, USA 28079

    SOURCE: Sunseeker North America

    View the original press release on ACCESS Newswire

    The post Sunseeker Launches Robotic Mowers on Lowe’s Online Platform appeared first on Local News Hub.

  • Boston Plastic Surgery Now Offers Motiva® Breast Implants, the Next Generation of Silicone Implants for Natural-Looking Results and Enhanced Safety

    Boston Plastic Surgery Now Offers Motiva® Breast Implants, the Next Generation of Silicone Implants for Natural-Looking Results and Enhanced Safety

    BOSTON, MA—Boston Plastic Surgery announces the addition of Motiva® silicone breast implants for breast augmentation to its list of breast implant options. As leaders in aesthetic medicine with a focus on innovation and patient-centered care, the practice is among the first plastic surgery centers in the Greater Boston area to offer this advanced implant technology.

    Motiva breast implants are FDA-approved and recognized for their next-generation design, offering patients new safety features while providing natural-looking aesthetic outcomes. Developed by Establishment Labs, these silicone implants incorporate several key advancements to address the most common concerns related to breast augmentation and implant replacement surgery.

    “We’re excited to offer our patients another safe and reliable breast implant option to personalize their procedure—especially an option that combines safety, beauty, and peace of mind,” said Dr. Fouad Samaha, board-certified plastic surgeon and founder of Boston Plastic Surgery. “The advanced safety technology behind Motiva implants has been proven to lower primary breast augmentation concerns such as implant rupture and capsular contracture.”

    Motiva implants offer a number of features that set them apart. The SmoothSilk® surface is engineered to reduce inflammation and the risk of capsular contracture—a complication in which scar tissue forms tightly around the implant, potentially distorting its shape and requiring corrective surgery. Motiva implants have impressively low rates of capsular contracture at just 0.5%.

    In addition, the BluSeal® barrier layer—a faint blue tint on the implant’s surface—enables surgeons to verify the structural integrity of the implant before it is placed. This added layer of visual confirmation serves as a simple but powerful tool to enhance safety in the operating room. Motiva’s rupture and infection rates are 0.6% and 0.9% respectively.

    Boston Plastic Surgery offers patients two styles of Motiva implants: the SmoothSilk® Round, which maintains its fullness and upper-pole projection regardless of body position, and the SmoothSilk® Ergonomix®, which is engineered to mimic the way natural breast tissue moves. The Ergonomix implant subtly shifts from a round to teardrop shape based on the body’s position, creating results that look natural when standing, lying down, or in motion.

    These implants are filled with highly cohesive silicone gel, which adds to their durability and provides a soft, natural feel. All Motiva implants are covered by a standard manufacturer’s warranty, with optional upgraded coverage for those seeking added confidence in their investment.

    Motiva implants offer a timely solution for natural breast augmentation, with terms like “Ballerina breast augmentation” and “petite breast augmentation” becoming increasingly popular for patients who seek subtle enhancement over more dramatic size changes.

    Dr. Samaha explained, “Motiva’s silicone implants are an excellent option to enhance the natural shape of the breast and fill out the breast pocket to create elegant cleavage without creating an obviously augmented look and maintaining a natural look and feel.”

    Whether a patient is pursuing primary breast augmentation or seeking to replace older implants with breast implant revision surgery, Boston Plastic Surgery ensures a fully personalized experience. Consultations with Dr. Samaha and Dr. Phelan include an in-depth discussion of implant options, sizing, placement techniques, and how Motiva may benefit the patient’s specific anatomy and desired outcome.

    “Motiva implants can give us more flexibility in technique, which means more customization for each patient’s body and goals,” said Dr. Phelan. “For example, because Motiva implants so closely mimic natural breast tissue, we can place them over-the-muscle with less concerns about visible implant rippling or an unnatural feel, even for patients with naturally thin breast tissue.”

    To learn more about Motiva silicone breast implants or schedule a personal consultation with Dr. Samaha or Dr. Phelan at Boston Plastic Surgery, located at 2300 Crown Colony Dr., Suite 101 Quincy, MA 02169, call 617-786-7600 or visit bostonplasticsurgery.com.

    The post Boston Plastic Surgery Now Offers Motiva® Breast Implants, the Next Generation of Silicone Implants for Natural-Looking Results and Enhanced Safety appeared first on Local News Hub.

  • essoc Voted Best No Show Socks for Its Stay-Put Comfort and Design

    essoc Voted Best No Show Socks for Its Stay-Put Comfort and Design

    NEW YORK, NY – essoc, a company renowned for its innovative approach to solving the universal and persistent problem of slipping no-show socks, has been officially voted the provider of the best no show socks in a comprehensive consumer poll and industry analysis. This significant accolade reflects the brand’s unwavering commitment to superior comfort, breakthrough innovation, and genuine inclusivity, setting a new and formidable standard in the everyday essentials market. The recognition validates essoc’s success in creating a product that consumers don’t just wear, but genuinely rely on.

    The inspiration behind essoc is drawn directly from the dynamic, stylish, and demanding lifestyle of its New York City home. The founder observed a fundamental disconnect: people invested in high-quality footwear for their fast-paced lives, only to be undermined by the constant distraction and discomfort of socks slipping down inside their shoes. This insight sparked a mission to engineer a solution. essoc designed socks that not only stay perfectly in place from the morning commute to a late-night social engagement but also feel like a seamless second skin. This unique and powerful combination of absolute functionality and sublime comfort has resonated deeply with consumers globally, leading directly to the brand earning this prestigious recognition.

    “Being recognized as the maker of the best no show socks is a profound testament to our team’s relentless dedication to quality and our core principle of listening intently to our customers’ needs,” said Stella Liu, founder of essoc. “Our mission was never just about making another sock. It was about meticulously re-engineering a fundamental wardrobe item to enhance everyday life, removing a small but significant friction point. This award is incredible validation that our efforts have made a real difference in the daily experience of our customers.”

    What truly distinguishes essoc in a crowded marketplace is its holistic approach to design. essoc has a design patent, which mainly protects their cutting technology and overall design.The company invested heavily in research and development, focusing on three key areas: a proprietary, skin-friendly silicone grip technology that provides a secure hold without irritation; an ergonomic, contoured fit that respects the natural shape of the human foot; and the use of premium, breathable fabric blends that ensure all-day freshness and prevent overheating. This trifecta of innovation directly addresses the primary complaints associated with conventional no-show socks—slipping, discomfort, and lack of durability.

    “Our socks are more than just a fashion accessory; they are a daily essential engineered to support and empower an active, modern lifestyle,” added Liu. “Whether you’re an executive running between meetings, a creative professional on your feet all day, or a parent navigating the city, your focus should be on your life, not on your socks. We are thrilled to be acknowledged for our commitment to this level of excellence and innovation, proving that even the most basic items can be perfected.”

    essoc’s success is deeply rooted in its ability to masterfully blend high-fashion sensibility with uncompromising practicality. The brand offers a product that flawlessly meets the sophisticated demands of modern living, ensuring that individuals never have to sacrifice style for comfort, or function for form. This unwavering focus on creating socks that provide uninterrupted, all-day comfort has allowed essoc to carve out a leadership position. The brand has demonstrated that consumers are eager to invest in high-quality essentials when they deliver tangible benefits and superior performance.

    As essoc continues to grow and innovate, this recognition as the best no show socks provider serves as a pivotal milestone. It marks a key moment in its journey to redefine what consumers can and should expect from their everyday apparel. Looking ahead, the brand remains passionately committed to pushing the boundaries of design and functionality, with plans to expand its range of materials and styles. essoc is dedicated to ensuring that its products not only remain at the forefront of the industry but continue to offer the perfect foundation for a confident and comfortable day.

    About essoc: essoc was created to solve a small but universal problem—no-show socks that slip off. Inspired by the active, stylish lifestyle of New York City, they designed socks that stay put, feel like a second skin, and keep feet comfortable all day. With a focus on comfort, innovation, and inclusivity, essoc is more than just a sock—it’s a daily essential made for real life. Stay focused. Stay comfortable. Stay put.

    Media Contact:
    hello@essoc.shop

    The post essoc Voted Best No Show Socks for Its Stay-Put Comfort and Design appeared first on Local News Hub.

  • Lex Wire Journal Features Attorney Jeff Howell’s Advanced AI Ethics Program

    Lex Wire Journal Features Attorney Jeff Howell’s Advanced AI Ethics Program

    Lex Wire Journal, the leading authority platform for attorney visibility in the digital age, today featured attorney Jeff Howell’s presentation of “Ethics in the Age of AI: Navigating Professional Responsibilities in Legal Practice,” a cutting-edge continuing legal education program delivered to the National Academy of Continuing Legal Education (NACLE) audience.

    Howell presented the essential CLE course addressing the critical challenge facing lawyers today: how to harness AI’s powerful capabilities while navigating complex ethical obligations that can make or break legal practice. His comprehensive program provided practical guidance for attorneys seeking to leverage AI tools like ChatGPT, Harvey AI, Relativity, and contract analysis platforms without stepping into ethical landmines that could result in sanctions, malpractice claims, or disciplinary action.

    Jeff Howell, Esq., smiling in a city street, alongside promotional banner for “Ethics in the Age of AI: Navigating Professional Responsibilities in Legal Practice” presentation for the National Academy of Continuing Legal Education, with Lex Wire Journal branding.

    In his presentation, Howell demonstrated how ABA Model Rules on competence, confidentiality, supervision, and fees apply directly to AI-assisted legal work. He provided NACLE participants with proven strategies for managing the real risks of AI bias, accuracy problems, data breaches, and overreliance on automated systems.

    As Jeff Howell, Esq., stated during his CLE presentation for the National Academy of Continuing Legal Education: “Don’t hit ‘generate’ and walk away. You’re still the lawyer. AI is just a very persuasive intern with no law degree.”

    Howell’s session combined implementation guidance, recent case studies including the landmark Mata v. Avianca sanctions, and practical compliance frameworks to help attorneys build robust AI governance systems. His presentation emphasized protecting clients, enhancing efficiency, and maintaining professional integrity in an increasingly AI-driven legal marketplace.

    The program addressed how established professional responsibility rules apply to artificial intelligence use in legal practice. Howell covered competence requirements, confidentiality obligations, supervision responsibilities, and fee considerations when using AI tools, providing attendees with actionable guidance for their own practices.

    Howell’s presentation included analysis of significant case studies, particularly the landmark Mata v. Avianca sanctions case, which demonstrated the serious consequences of improper AI use in legal practice. He emphasized practical compliance frameworks that attorneys can immediately implement to avoid common pitfalls while maximizing AI benefits.

    A significant portion of Howell’s training focused on identifying and managing AI-related risks in legal practice, including AI bias recognition and mitigation, accuracy and verification protocols, data security and breach prevention, and avoiding overreliance on automated systems. His comprehensive approach provided attendees with tools to navigate the complex ethical landscape of AI implementation.

    Howell’s presentation to the NACLE audience reflects his expertise in maintaining the highest professional standards while embracing technological innovation. As AI tools become increasingly prevalent in legal practice, attorneys who understand the ethical implications gain significant advantages in serving clients effectively and avoiding professional liability.

    The cutting-edge program addressed continuing legal education requirements while tackling emerging challenges in legal practice. As state bars increasingly recognize the importance of AI ethics education, Howell’s presentation demonstrates thought leadership in professional competence and client protection.

    Howell’s delivery of this advanced ethics training positions him as a leader in responsible AI adoption within the legal profession. As courts and regulatory bodies develop new standards for AI use in legal practice, his expertise in AI ethics helps attorneys prepare for changing requirements and maintain ethical compliance.

    “The trend is moving toward more disclosure and more accountability, not less,” said attorney Jeff Howell in his recent CLE presentation.

    The presentation provided NACLE participants with practical frameworks for ongoing AI governance, ensuring they can adapt to new technologies while maintaining ethical compliance. Howell’s proactive approach to professional responsibility demonstrates leadership in navigating the evolving legal landscape.

    Jeff Howell is an attorney recognized for his expertise in AI ethics and professional responsibility in legal practice. His presentation to the National Academy of Continuing Legal Education demonstrates his commitment to advancing the legal profession’s understanding of ethical AI implementation.

    The National Academy of Continuing Legal Education provides comprehensive MCLE programming that meets state requirements, offering specialized courses addressing evolving professional responsibility challenges in technology adoption.

    The complete Lex Wire Journal feature article about Jeff Howell’s AI ethics presentation can be viewed at https://lexwire.org/news/advanced-ai-ethics-training

    The post Lex Wire Journal Features Attorney Jeff Howell’s Advanced AI Ethics Program appeared first on Local News Hub.

  • Harmony & Healing Launches Private Benefit Concert Program, Turning Backyards Into Unforgettable Fundraisers

    Harmony & Healing Launches Private Benefit Concert Program, Turning Backyards Into Unforgettable Fundraisers

    Harmony & Healing has announced the launch of its new Private Benefit Concert program, bringing the energy and connection of live music directly into backyards, wineries, corporate spaces, and private event venues. These intimate, high-energy concert/dance parties not only create unforgettable evenings for hosts and their guests, they also raise vital funds to provide free live musical visits to patients in hospitals, hospices, rehab facilities, and memory care centers.

    The Private Benefit Concert program offers hosts a turnkey way to throw an extraordinary party with a purpose. Harmony & Healing founder David Victor, a former member of the multi-platinum band BOSTON, performs alongside drummer Michael Brandon and bassist Russell Vazquez in their powerhouse trio, “Therapy Dawgs”. The band delivers multiple sets of crowd-pleasing, danceable hits, transforming private venues into unforgettable live music experiences.

    Unlike large, formal benefit concerts that require complex logistics, these events are designed to be simpler for the host. Harmony & Healing handles the performance, lighting, sound, and crew, while the host focuses on food and beverages and inviting friends, family, and colleagues to enjoy the show. These events also feature a lively live auction, with prizes such as autographed guitars, exclusive wine tastings, vacation getaways, and VIP tickets to major sporting events or concerts.

    Early hosts are already sharing glowing reviews. Joe Schembri, who hosted a Private Benefit Concert in Danville in June 2025, said, “The energy was absolutely incredible. David and his band brought such professionalism and heart to our backyard. Our guests are still talking about it months later.” In August 2025, Pleasanton host Geoff Rodgers added, “I was worried about logistics, but the team made it so easy. We raised significant funds while creating memories that will last a lifetime.”

    The concept works because it creates an exclusive, intimate atmosphere that cannot be replicated in larger venues. Guests enjoy the rare experience of a private concert by professional musicians in a relaxed, familiar setting, while knowing that their participation is helping to fund a meaningful cause. Every dollar raised supports Harmony & Healing’s mission to provide no-cost, live musical visits both in-person and via Zoom to patients of all ages and their loved ones.

    Founded by David Victor in the San Francisco Bay Area, Harmony & Healing has become known for its compassionate approach to using music as a tool for emotional connection, stress reduction, and joy. These musical visits are not formal music therapy, but rather carefully curated performances that tap into patients’ most cherished memories and associations. The organization’s professional musicians are selected not only for their talent but for their ability to connect on a personal level with patients, families, and caregivers.

    Private Benefit Concerts are an extension of that mission, allowing supporters to bring the same level of artistry and connection into their own communities while raising the funds that make the free patient visits possible. The money generated from each concert directly supports the organization’s roster of artists, ensuring that patients and their families never pay for the performances they receive.

    The need for this work is ongoing. Patients in hospitals, hospices, and long-term care facilities often face long days filled with medical procedures and uncertainty. For many, a live musical visit is a welcome break that lifts spirits, rekindles happy memories, and provides moments of genuine human connection. These visits also reach veterans living with PTSD, children in pediatric care, and individuals in memory care, where music can stimulate recognition and response even when other forms of communication have faded.

    Victor sees the Private Benefit Concert program as a way to deepen community engagement while sustaining the charity’s impact year-round. “A Private Benefit Concert is more than just a party,” he explained. “It’s a way to connect with your friends and neighbors through great music, while knowing that the joy you experience that night is directly bringing comfort and healing to patients in hospice, rehab and hospitals who truly need it.”

    Harmony & Healing encourages interested hosts to think creatively about their venues. While many concerts take place in spacious backyards, others are held in wineries, community centers, or corporate settings. The key is creating a welcoming space where guests can relax, enjoy the music, and participate in the fundraising activities.

    The organization provides guidance on event flow, auction timing, and promotion to make each concert as successful as possible. From the moment the band arrives for setup to the final encore, hosts can relax knowing the details are handled. The result is an evening that strengthens community bonds, celebrates live music, and funds a mission that touches lives across the country.

    To learn more about hosting a Private Benefit Concert and becoming part of this growing movement, visit the Harmony & Healing website.

    The post Harmony & Healing Launches Private Benefit Concert Program, Turning Backyards Into Unforgettable Fundraisers appeared first on Local News Hub.

  • Building Tomorrow: Unleashing the Power of Structural Fabrication With AGI Fabricators.

    Building Tomorrow: Unleashing the Power of Structural Fabrication With AGI Fabricators.

    AGI Fabricators, a provider of metal structural fabrication solutions, today emphasizes the breadth of its fabrication and welding services for complex industrial and commercial projects. The company highlights certified welding procedures, in-house structural engineering, catalog fabrication drawings and multi-material capabilities, positioning its team and plant resources as responsive to regulatory specifications, project schedules and cross-industry needs including chemical, pharmaceutical and material handling sectors.

    The company operates a state-of-the-art facility with modern fabrication equipment and a workforce experienced across materials, grades and design disciplines. AGI Fabricators brings more than 125 years of combined experience and 25 years specifically in structural service work, with capacity for complex custom assemblies, detailed fabrication drawings and the use of CAD tools such as AutoCAD, Revit, SketchUp and SolidWorks.

    steel structural fabrication example work from AGI Fabricators

    Regional engineering firms and owner-operators rely on AGI’s structural fabrication capabilities when specifying certified welding and detailed member design for tight schedules. The company maintains SMAW and GMAW procedures that meet AWS D1.1 for carbon structural steel and AWS D1.6 for stainless, along with field welding technicians certified in SMAW structural processes to support site work while preserving quality control and compliance with industry standards.

    “Meeting AWS D1.1 and D1.6 expectations on high-cycle industrial projects requires integrated planning between engineers, welders and project managers,” said Brad Landry, General Manager at AGI Fabricators. “Our approach aligns certified welding procedures, in-house inspection and fabrication sequencing to reduce rework and maintain traceability across shop assemblies and delivered components while supporting tight proposal and lead time requirements.”

    AGI Fabricators integrates structural engineering with shop-floor practices through design review, structural member analysis and efforts to minimize unnecessary support material through optimized member sizing. The process includes conceptual drawings, rough order of magnitude estimates, development of catalog fabrication drawings, and coordination of painting, assembly and trucking to meet site handover milestones and installation schedules.

    “Our teams focus on practical fabrication sequencing and coordination with owners and installers to streamline delivery and erection-ready assemblies,” said Brad Landry, General Manager at AGI Fabricators. “That includes detailed shop drawings, certified weld documentation, a certified weld inspector on staff, and coordination of value-added services such as painting, assembly and trucking to accelerate installation and reduce field time.”

    AGI Fabricators maintains personnel qualifications that underpin shop performance, including certified catalog and field welders, project managers with structural fabrication experience and an in-house certified weld inspector to verify compliance. The factory workflow encompasses initial scope development, estimating, design approval, structural engineering, fabrication and installation coordination, with annual inspection reporting available when required for lifecycle documentation and regulatory audits.

    The company serves target markets across chemical processing, environmental equipment, food processing and pollution control, delivering repeatable processes for material handling and pharmaceutical clients with strict cleanliness and traceability needs. AGI Fabricators offers short proposal turnaround, minimal project commencement lead time, and the capacity to manage custom configurations that require complex welding, fit-up and finish work to precise tolerances.

    AGI Fabricators maintains quality systems and safety practices tied to its welding certifications, adhering to SMAW and GMAW procedures for both carbon and stainless steels and operational controls for weld procedure specifications. The company integrates certified weld documentation and inspector sign-off into deliverables to support client quality audits, third-party reviews and compliance with plant safety and maintenance planning.

    The company provides logistical and value-added services that support end-to-end delivery, including in-house fabrication drawings, assembly, painting and trucking coordination, while noting limitations such as the exclusion of concrete reinforcement steel work and field steel erecting services. These services complement in-shop engineering and welding capabilities, enabling clients to receive erection-ready structural components with accompanying documentation and transport scheduling.

    AGI Fabricators invites interested owners and contractors to engage its structural fabrication team for projects requiring AWS D1.1 and D1.6 certified welding, in-house structural engineering, catalog and fabrication drawings, assembly, painting and trucking, with availability aligned to the firm’s short proposal turnaround and minimal project commencement lead time.

    The post Building Tomorrow: Unleashing the Power of Structural Fabrication With AGI Fabricators. appeared first on Local News Hub.